Eperisone

Eperisone

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	O
ATC code	M03BX09 (WHO)
Legal status
Legal status	not licensed
Identifiers
IUPAC name (2RS)-1-(4-ethylphenyl)-2-methyl-3-(1-piperidyl)propan-1-one
CAS Number	56839-43-1 N
PubChem CID	3236
DrugBank	DB08992 N
ChemSpider	3123 Y
UNII	2M2P0551D3
KEGG	D01671 Y
ChEBI	CHEBI:77069 N
ChEMBL	ChEMBL1902981 N
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C17H25NO
Molar mass	259.387 g/mol
InChI InChI=1S/C17H25NO/c1-3-15-7-9-16(10-8-15)17(19)14(2)13-18-11-5-4-6-12-18/h7-10,14H,3-6,11-13H2,1-2H3 Y Key:SQUNAWUMZGQQJD-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

WikiDoc Resources for Eperisone
Articles
Most recent articles on Eperisone Most cited articles on Eperisone Review articles on Eperisone Articles on Eperisone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Eperisone Images of Eperisone Photos of Eperisone Podcasts & MP3s on Eperisone Videos on Eperisone
Evidence Based Medicine
Cochrane Collaboration on Eperisone Bandolier on Eperisone TRIP on Eperisone
Clinical Trials
Ongoing Trials on Eperisone at Clinical Trials.gov Trial results on Eperisone Clinical Trials on Eperisone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Eperisone NICE Guidance on Eperisone NHS PRODIGY Guidance FDA on Eperisone CDC on Eperisone
Books
Books on Eperisone
News
Eperisone in the news Be alerted to news on Eperisone News trends on Eperisone
Commentary
Blogs on Eperisone
Definitions
Definitions of Eperisone
Patient Resources / Community
Patient resources on Eperisone Discussion groups on Eperisone Patient Handouts on Eperisone Directions to Hospitals Treating Eperisone Risk calculators and risk factors for Eperisone
Healthcare Provider Resources
Symptoms of Eperisone Causes & Risk Factors for Eperisone Diagnostic studies for Eperisone Treatment of Eperisone
Continuing Medical Education (CME)
CME Programs on Eperisone
International
Eperisone en Espanol Eperisone en Francais
Business
Eperisone in the Marketplace Patents on Eperisone
Experimental / Informatics
List of terms related to Eperisone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Eperisone (formulated as the eperisone hydrochloride salt) is an antispasmodic drug.

Eperisone acts by relaxing both skeletal muscles and vascular smooth muscles, and demonstrates a variety of effects such as reduction of myotonia, improvement of circulation, and suppression of the pain reflex. The drug inhibits the vicious circle of myotonia by decreasing pain, ischaemia, and hypertonia in skeletal muscles, thus alleviating stiffness and spasticity, and facilitating muscle movement

Eperisone also improves dizziness and tinnitus associated with cerebrovascular disorders or cervical spondylosis.

Eperisone has a relatively low incidence of sedation when compared with other antispasmodic drugs; this simplifies the clinical application of the drug and makes it an attractive choice for patients who require antispasmodic therapy without a reduction in alertness.

Eperisone also facilitates voluntary movement of the upper and lower extremities without reducing muscle power; it is therefore useful during the initial stage of rehabilitation and as a supporting drug during subsequent rehabilitative therapy.

Indications

• Spastic paralysis in conditions such as cerebrovascular disease
• Spastic spinal paralysis
• Cervical spondylosis
• Postoperative sequelae (including from cerebrospinal tumour)
• Sequelae to trauma (e.g. spinal trauma or head injury)
• Amyotrophic lateral sclerosis
• Cerebral palsy
• Spinocerebellar degeneration
• Spinal vascular diseases and other encephalomyelopathies
• Cervical syndrome, periarthritis of the shoulder, and lumbago.

Presentation

Eperisone hydrochloride is available as the brand name preparation Myonal as 50 mg sugar coated tablets, or as 10% granules for oral administration. An experimental form of the drug, as a transdermal patch system, has shown promising results in laboratory tests on rodents; however, this product is not currently available for human use. It is also available as the brand name Epry as 50 mg as sugar coated tablets.

Dosage and administration

In adults, the usual dose of eperisone is 50–150 mg per day, in divided doses, after meals. However, the dosage is adjusted by the prescribing clinician depending on factors such as severity of symptoms, patient age and response.

Eperisone has not been established as definitely safe for paediatric use, therefore its use in paediatrics cannot be recommended without further study.

If elderly patients are treated with eperisone, a reduced dose is recommended, and the patient should be closely monitored for signs of psychological hypofunction during treatment.

Safety during pregnancy and breast-feeding

Eperisone has not been established to be safe for use by pregnant women; therefore the drug should only be used in pregnant women, or women who may be pregnant, if the expected therapeutic benefits will outweigh the possible risks associated with treatment. The manufacturers of Myonal recommend the drug not be used during lactation (breast-feeding). If eperisone must be used, the patient is advised to stop breast-feeding for the duration of treatment. Eperisone has beed reported to be excreted in breast milk in an animal study (in rats).

Pharmacology

• Skeletal muscle relaxation
• Relaxation of hypertonic skeletal muscles
• Improves intramuscular blood flow
• Suppression of spinal reflex potentials
• Reduction of muscle spindle sensitivity via motor neurons
• Vasodilatation and augmentation of blood flow
• Analgesic action and inhibition of the pain reflex in the spinal cord

Contraindications

Eperisone is contraindicated in patients with known hypersensitivity to the drug. Side effects: 'very rare' excessive relaxation, stomachache, nausea, vertigo, anorexia, drowsiness, skin rashes, diarrhoea, vomiting, indigestion, GI disturbances, insomnia, headache, constipation etc.

Cautions

Eperisone should be administered with care in patients with a history of hypersensitivity to any medication, or with disorders of liver function (it may aggravate hepatic dysfunction).

Weakness, light-headedness, sleepiness or other symptoms may occur. In the event of such symptoms, the dosage should be reduced or treatment discontinued. Patients should be cautioned against engaging in potentially hazardous activities requiring alertness, such as operating machinery or driving a car.

Side effects

• Shock and anaphylactoid reactions: In the event of symptoms such as redness, itching, urticaria, oedema of the face and other parts of the body, dyspnoea, etc., treatment should be discontinued and appropriate measues taken.
• Other side effects: anaemia, rash, pruritus, sleepiness, insomnia, headache, nausea and vomiting, anorexia, abdominal pain, diarrhoea, constipation, urinary retention or incontinence.

Drug interactions

There have been reports of disturbances in ocular accommodation occurring after the concomitant use of the related drug tolperisone hydrochloride and methocarbamol.

Safety in overdose

Seizures have been reported in an infant after accidental ingestion of eperisone.

Future developments

Eperisone suffers from a very low bioavailability when taken orally, as a result of high first pass intestinal metabolism; a transdermal patch containing eperisone is currently in development in South Korea. This has shown promise, with the antispasmodic effect lasting over 24 hours, compared to one to two hours following oral administration.

Eperisone is also under investigation as an antihypertensive agent, with promising results from trials on beagles.

Brand names

Eperisone is sold in Bangladesh, China, India, Indonesia, Japan, United Arab Emirates, Malaysia, the Philippines, Thailand, Sudan and Pakistan under the brand name Myonal and in Italy under the brand name Expose.

See also

• Chemically and mechanistically related drugs: inaperisone, lanperisone, silperisone, tolperisone

References

• Fujioka M, Kuriyama H (December 1985). "Eperisone, an antispastic agent, possesses vasodilating actions on the guinea-pig basilar artery". J. Pharmacol. Exp. Ther. 235 (3): 757–63. PMID 3935775.
• Inoue S, Bian K, Okamura T, Okunishi H, Toda N (July 1989). "Mechanisms of action of eperisone on isolated dog saphenous arteries and veins" (– ^{Scholar search}). Jpn. J. Pharmacol. 50 (3): 271–82. doi:10.1254/jjp.50.271. PMID 2761129.CS1 maint: Multiple names: authors list (link)
• Viveksarathi, K., et al. "Dosage form design and evaluation of eperisone hydrochloride matrix film coated extended release tablets." Int J Pharm Pharm Sci 4.2 (2012): 575-581. http://www.ijppsjournal.com/Vol4Issue2/3559.pdf